Aim: .The study's objective is to analyze the safety and efficacy of glycomet vs insulin in the treatment of gestational diabetes mellitus. Objective: The objective is to compare safety and efficacy of glycogen and insulin. Methodology: The goal of this study is to see how safe and effective insulin and glycomet are in the monitoring for GDM patients. Baseline demographic data is gathered using patient case records. The obtained data is statistically reviewed and evaluated. The patient's medical record and laboratory reports are used to obtain all necessary information or data. Results: The demographics of the patients who matched the inclusion criteria were reviewed, and it was revealed that glycomet is a safer and more effective treatment for gestational diabetes mellitus. - Everypregnant woman, regardless of age or parity - A gestational age of 14 to 36 weeks -We used a total of 60 patients in this study, who were then divided evenly based on their age, indications, and gestation week, with a p value of 0.03. Conclusion: In summary, metformin has been proven to be safe and beneficial in the treatment of gestational diabetes mellitus in pregnant women, with no maternal or newborn problems when compared to insulin, and a low risk of caesarian sections .When compared to insulin, metformin was shown to be both safe and effective in reducing blood sugar levels. When insulin was used, there were a lot of caesarian sections. There is no danger of hyperglycemia when using metformin. When compared to insulin injections, metformin is easier for the patient to deliver because it is taken orally. In comparison to insulin, metformin is inexpensive, simple, fast, and convenient to use . Maternal and neonatal outcomes were nearly identical in both groups. However, one patient switched from metformin to insulin treatment.
